help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franklin, S. L.
Right arrow Articles by Cohen, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franklin, S. L.
Right arrow Articles by Cohen, P.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 2 900-907
Copyright © 2003 by The Endocrine Society

Rapid Insulin-Like Growth Factor (IGF)-Independent Effects of IGF Binding Protein-3 on Endothelial Cell Survival

Sherry Lynn Franklin, Robert J. Ferry, Jr. and Pinchas Cohen

Division of Pediatric Endocrinology and Diabetes (S.L.F., P.C.), Mattel Children’s Hospital, University of California, Los Angeles, California 90095-1752; and Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics (R.J.F.), The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900

Address all correspondence and requests for reprints to: Robert J. Ferry, Jr., M.D., Director of Research and Training, Division of Pediatric Endocrinology, Department of Pediatrics, The University of Texas Health Science Center at San Antonio, 528L-2 MSC 7806, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900. E-mail: bob{at}uthscsa.edu.

Angiogenic factors, such as vascular endothelial-derived growth factor (VEGF) and IGF-I, play pivotal roles in endothelial proliferation and migration. IGF binding protein-3 (IGFBP-3) is emerging as a key regulator of cell growth and apoptosis, both as an IGF antagonist and as an independent molecule. We investigated the role of IGFBP-3 in VEGFmediated survival of human macrovascular umbilical vein endothelial cells (HUVEC). Specific commercial ELISAs quantified cell proliferation and apoptosis, and Akt phosphorylation was assessed by immunoblots and confocal microscopy. IGF-I and VEGF significantly stimulated HUVEC proliferation and survival. Addition of IGFBP-3 reversed both IGF- and VEGF-induced proliferation and prevented the survival induced by these factors. The antiproliferative and proapoptotic effects of exogenous IGFBP-3 upon VEGF-induced HUVEC survival were not inhibited by blockade of the type 1 IGF receptor with {alpha}IR-3 immunoglobulin, which fully prevented IGF actions. An IGFBP-3 mutant, which binds IGFs normally but has a substituted mid-region domain, lost the ability to inhibit VEGF actions. VEGF-induced phosphorylation of Akt, as evident by both specific immunoblots and confocal microscopy, was significantly and rapidly reduced in the presence of IGFBP-3, as well as wortmannin.

This work was supported in part by NIH Grants 2R01-DK-47591, 1RO1-AI-40203, 1R01-AG-20954, and 1UO1-CA-84128 (to P.C.); 5T32-DK-007688 (to S.L.F.); K08-DK-02876 and 5P30-HD-34610 (to R.F.); grants from the Juvenile Diabetes Foundation; and a Pharmacia GEM grant (to P.C.) as well as a fellowship award from Eli Lilly (to S.L.F.).

Abbreviations: DAPI, 4',6-Diamidino-2-phenylindole; EGM-2-MV Bullet Kit, Microvascular Endothelial Cell Growth Medium Bullet Kit-2; FITC, fluorescein isothiocyanate; HBD, heparin-binding domain; HUVEC, human macrovascular umbilical vein endothelial cells; IGF1R, type 1 IGF receptor; IGFBP-3, IGF binding protein-3; PI3-kinase, phosphatidylinositol 3'-kinase; SDS, sodium dodecyl sulfate; SFM, serum-free medium; VEGF, vascular endothelial-derived growth factor.




This article has been cited by other articles:


Home page
EndocrinologyHome page
G. Zappala, C. Elbi, J. Edwards, J. Gorenstein, M. M. Rechler, and N. Bhattacharyya
Induction of Apoptosis in Human Prostate Cancer Cells by Insulin-Like Growth Factor Binding Protein-3 Does Not Require Binding to Retinoid X Receptor-{alpha}
Endocrinology, April 1, 2008; 149(4): 1802 - 1812.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. Gray, J. T. Mao, E. Szabo, M. Kelley, J. Kurie, and G. Bepler
Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 56S - 68S.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Lofqvist, J. Chen, K. M. Connor, A. C. H. Smith, C. M. Aderman, N. Liu, J. E. Pintar, T. Ludwig, A. Hellstrom, and L. E. H. Smith
From the Cover: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth
PNAS, June 19, 2007; 104(25): 10589 - 10594.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K.-H. Chang, T. Chan-Ling, E. L. McFarland, A. Afzal, H. Pan, L. C. Baxter, L. C. Shaw, S. Caballero, N. Sengupta, S. L. Calzi, et al.
IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development
PNAS, June 19, 2007; 104(25): 10595 - 10600.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. M.E.I. Hellebrekers, V. Melotte, E. Vire, E. Langenkamp, G. Molema, F. Fuks, J. G. Herman, W. Van Criekinge, A. W. Griffioen, and M. van Engeland
Identification of Epigenetically Silenced Genes in Tumor Endothelial Cells
Cancer Res., May 1, 2007; 67(9): 4138 - 4148.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. H. Muzumdar, X. Ma, S. Fishman, X. Yang, G. Atzmon, P. Vuguin, F. H. Einstein, D. Hwang, P. Cohen, and N. Barzilai
Central and Opposing Effects of IGF-I and IGF-Binding Protein-3 on Systemic Insulin Action.
Diabetes, October 1, 2006; 55(10): 2788 - 2796.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
L. M. Schnapp, S. Donohoe, J. Chen, D. A. Sunde, P. M. Kelly, J. Ruzinski, T. Martin, and D. R. Goodlett
Mining the Acute Respiratory Distress Syndrome Proteome: Identification of the Insulin-Like Growth Factor (IGF)/IGF-Binding Protein-3 Pathway in Acute Lung Injury
Am. J. Pathol., July 1, 2006; 169(1): 86 - 95.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
I. Peters, I. Tossidou, J. Achenbach, R. Woroniecki, M. Mengel, J.-K. Park, M. Paschy, K. de Groot, H. Haller, and M. Schiffer
IGF-Binding Protein-3 Modulates TGF-beta/BMP-Signaling in Glomerular Podocytes
J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1644 - 1656.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. Cohen
Insulin-like growth factor binding protein-3: insulin-like growth factor independence comes of age.
Endocrinology, May 1, 2006; 147(5): 2109 - 2111.
[Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. M.E.I. Hellebrekers, K.-W. Jair, E. Vire, S. Eguchi, N. T.H. Hoebers, M. F. Fraga, M. Esteller, F. Fuks, S. B. Baylin, M. van Engeland, et al.
Angiostatic activity of DNA methyltransferase inhibitors.
Mol. Cancer Ther., February 1, 2006; 5(2): 467 - 475.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S.-H. Oh, W.-Y. Kim, J.-H. Kim, M. N. Younes, A. K. El-Naggar, J. N. Myers, M. Kies, P. Cohen, F. Khuri, W. K. Hong, et al.
Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., January 15, 2006; 12(2): 653 - 661.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J.-Y. Han, S. H. Oh, F. Morgillo, J. N. Myers, E. Kim, W. K. Hong, and H.-Y. Lee
Hypoxia-inducible Factor 1{alpha} and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer
J Natl Cancer Inst, September 7, 2005; 97(17): 1272 - 1286.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K.-W. Lee, L. Ma, X. Yan, B. Liu, X.-k. Zhang, and P. Cohen
Rapid Apoptosis Induction by IGFBP-3 Involves an Insulin-like Growth Factor-independent Nucleomitochondrial Translocation of RXR{alpha}/Nur77
J. Biol. Chem., April 29, 2005; 280(17): 16942 - 16948.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. V. Silha, Y. Gui, S. Mishra, A. Leckstrom, P. Cohen, and L. J. Murphy
Overexpression of Gly56/Gly80/Gly81-Mutant Insulin-Like Growth Factor-Binding Protein-3 in Transgenic Mice
Endocrinology, March 1, 2005; 146(3): 1523 - 1531.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Pold, K. Krysan, A. Pold, M. Dohadwala, N. Heuze-Vourc'h, J. T. Mao, K. L. Riedl, S. Sharma, and S. M. Dubinett
Cyclooxygenase-2 Modulates the Insulin-Like Growth Factor Axis in Non-Small-Cell Lung Cancer
Cancer Res., September 15, 2004; 64(18): 6549 - 6555.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K.-W. Lee, B. Liu, L. Ma, H. Li, P. Bang, H. P. Koeffler, and P. Cohen
Cellular Internalization of Insulin-like Growth Factor Binding Protein-3: DISTINCT ENDOCYTIC PATHWAYS FACILITATE RE-UPTAKE AND NUCLEAR LOCALIZATION
J. Biol. Chem., January 2, 2004; 279(1): 469 - 476.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. B. Twickler, M. J. M. Cramer, G. M. Dallinga-Thie, M. J. Chapman, D. W. Erkelens, and H. P. F. Koppeschaar
Adult-Onset Growth Hormone Deficiency: Relation of Postprandial Dyslipidemia to Premature Atherosclerosis
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2479 - 2488.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society